Ezzedine Salah, Bege Thierry, Berdah Stephan, Vitton Veronique, Grimaud Jean-Charles, Barthet Marc
Department of Gastroenterology, Hôpital Nord, Marseille, France.
Surg Laparosc Endosc Percutan Tech. 2010 Dec;20(6):e230-2. doi: 10.1097/SLE.0b013e318200a115.
Angiogenesis inhibitors have markedly improved, in combination with chemotherapy, the outcome of patients with metastatic solid tumors. Bevacizumab, the brand name of which is Avastin, is the first monoclonal antibody IgG1 used against the vascular endothelial growth factor involved in tumor proliferation. Gastrointestinal perforation is a well-known adverse event of bevacizumab therapy. Its surgical management is still controversial because of the high mortality rate of surgery. Here, we report a 48-year-old man with a history of metastatic renal cancer, who developed colonic perforation secondary to bevacizumab. This patient was treated successfully with endoscopic stenting.
血管生成抑制剂与化疗联合使用，显著改善了转移性实体瘤患者的治疗效果。贝伐单抗，商品名为阿瓦斯汀，是首个用于对抗参与肿瘤增殖的血管内皮生长因子的单克隆抗体IgG1。胃肠道穿孔是贝伐单抗治疗众所周知的不良事件。由于手术死亡率高，其手术治疗仍存在争议。在此，我们报告一名48岁有转移性肾癌病史的男性，他因贝伐单抗继发结肠穿孔。该患者通过内镜支架置入术成功治愈。
